English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

TET2  is involved in a variety of hematopoietic malignancies, mainly in myeloid malignancies. Most mutations of  TET2  have been identified in myeloid disorders, but some have also recently been described in mature lymphoid neoplasms. In contrast to the large amount of data about mutations of  TET2 , some data are available for gene expression. Moreover, the role of TET2 in chronic lymphocytic leukemia (CLL) is unknown. This study analyzes both  TET2  expression and mutations in 48 CLL patients.  TET2  expression was analyzed by exon arrays and quantitative real-time polymerase chain reaction (qRT-PCR). Next-generation sequencing (NGS) technology was applied to investigate the presence of  TET2  variations. Overexpression of  TET2  was observed in B-cell lymphocytes from CLL patients compared with healthy donors ( P  = 0.004). In addition, in CLL patients, an overexpression of  TET2  was also observed in the clonal B cells compared with the nontumoral cells ( P  = 0.002). However, no novel mutations were observed. Therefore, overexpression of  TET2  in CLL seems to be unrelated to the presence of genomic  TET2  variations.

TET2Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence ofTET2Variations